← All indications
Nerve Sheath Neoplasms
Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.
Subtype terms (3)
More specific conditions that are subtypes of Nerve Sheath Neoplasms in the MeSH hierarchy.
- Neurofibroma
32 drugs (21 approved, 11 experimental)
- Neuroma
6 drugs approved
- Neurothekeoma
Drugs by status
Phase 4 trials (8)
Phase 3 trials (5)
Phase 2 trials (34)
- apg-115
- temsirolimus
- cixutumumab
- vismodegib
- gemcitabine
- tacrolimus
- lorvotuzumab mertansine
- pembrolizumab
- alisertib
- ro4929097
- sapanisertib
- sirolimus
- cyclosporine
- mycophenolate
- ganetespib
- tazemetostat
- Anti-thymocyte Globulin (Rabbit)
- zoledronic acid
- bakuchiol
- titanium
- zinc dichloride
- fludarabine
- selumetinib
- thiotepa
- avobenzone
- ecamsule
- etoposide
- sodium chloride
- melphalan
- isotretinoin
- +4 more
Phase 1 trials (5)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (25)
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- Genentech
- Plexxikon
- Bayer
- Synta Pharmaceuticals Corp.
- Cornell University
- Harvard University
- Northwestern University
- Oregon Health and Science University
- Osaka University
- Sarcoma Alliance for Research through Collaboration
- Southwest Oncology Group
- University of Michigan
- Columbia University
- University of California, Los Angeles
- University of Utah
- Department of Defense
- University of Texas at Houston
- Maria Sklodowska Curie Children's Hospital
- Washington University in St. Louis
- Children's National Medical Center
- National Comprehensive Cancer Network
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (2)